The new World Health Organisation classification for tumors of the digestive system is expected at the end of 2018. This classification forms the basis for diagnostics and treatment of cancer and their precursors. Authors and editors are selected based on international impact and publications over the last five years.Iris Nagtegaal (Pathology, leader of the research theme Tumors of the digestive tract) will be leading editor on colorectal and appendiceal tumors.
Illustrative for the prominent role of the Radboudumc in hereditary cancers (National Expertise Center, ERN Genturis): our gastrointestinal pathologist are authors on hereditary gastric cancer (Chella van der Post), hereditary pancreatic cancer (Lodewijk Brosens), hamartomatous polyposis syndromes (Lodewijk Brosens) and Lynch syndrome (Iris Nagtegaal).
Related news items
Rebecca Halbach receives poster prize at EMBO conference20 September 2018
Rebecca Halbach, theme Infectious diseases and global health, has received a poster prize at the EMBO Workshop ‘piRNAs and PIWI proteins’, held in Montpellier, France.read more
Netherlands X-omics Initiative: Consortium kick off meeting20 September 2018
The Netherlands X-omics Initiative had their consortium kick-off meeting. Consortium members from the Dutch partners involved gathered to get to know each other and to determine the next steps to start up the project.read more
A personal touch of Carine van der Vleuten20 September 2018
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t! This week: Carine van der Vleuten.read more
Rectal cancer staging using MRI with endorectal filling19 September 2018
In the British Journal of Radiology Rutger Stijns and colleagues, showed that using MRI with endorectal filling did not lead to an improved rectal cancer staging and that it has the potential to influence the distance to a key anatomical landmark.read more
Low risk of progression in persistent non-dysplastic Barrett’s esophagus19 September 2018
In Clinical Gastroenterology and Hepatology Peter Siersema and Yonne Peters showed that patients with stable persistence of non-dysplastic Barrett’s esophagus have a low risk of malignant progression and may not benefit from routine endoscopic surveillance.read more